Impact of empagliflozin on blood pressure in dipper and non‐dipper patients with type 2 diabetes mellitus and hypertension
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
In the EMPA‐REG BP trial, empagliflozin significantly reduced systolic and diastolic blood pressure ( SBP and DBP ) compared with placebo at week 12 in patients with type 2 diabetes mellitus ( T2DM ) and hypertension. In a post‐hoc analysis, we assessed the effect of empagliflozin on SBP and DBP using 24‐hour ambulatory BP monitoring in patients categorized as dippers (sleep‐time mean SBP ≤ 90% of awake‐time mean; n = 417) or non‐dippers (sleep‐time mean SBP > 90% of awake‐time mean; n = 350). In dippers, adjusted mean ( SE ) changes from baseline in mean 24‐hour SBP ( mm Hg ) at week 12 were −0.2 (0.7) with placebo vs −3.8 (0.6) and −3.9 (0.7) with empagliflozin 10 and 25 mg, respectively (both P < .001 vs placebo). In non‐dippers, these changes were 1.0 (0.7) with placebo vs −1.6 (0.7) with empagliflozin 10 mg ( P = .013 vs placebo) and −3.8 (0.7) with empagliflozin 25 mg ( P < .001 vs placebo). In both dippers and non‐dippers, SBP and DBP patterns over 24 hours were maintained. There were no clinically relevant changes in heart rate with empagliflozin. In conclusion, empagliflozin significantly reduced mean 24‐hour SBP compared with placebo in dippers and non‐dippers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationChilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12572 · Cited by 507
Self-citationEmpagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension
Tikkanen, I., Narko, K., Zeller, C., Green, A., Salsali, A., Broedl, U. C., & Woerle, H. J. (2015) · Diabetes Care · doi:10.2337/dc14-1096 · Cited by 468 · cited 4×
“In the EMPA-REG BP trial, treatment with empagliflozin 10 or 25 mg qd for 12 weeks significantly reduced SBP and DBP compared with placebo in patients with T2DM and hypertension.(9) In this post-hoc subgroup analysis, we have shown that treatment with empagliflozin significantly reduced SBP compared with placebo in di…”
MethodResultSelf-citationPrevalence and Factors Associated With Circadian Blood Pressure Patterns in Hypertensive Patients
de la Sierra, A., Redon, J., Banegas, J. R., Segura, J., Parati, G., Gorostidi, M., de la Cruz, J. J., Sobrino, J., Llisterri, J. L., Alonso, J., et al. (2009) · Hypertension · doi:10.1161/hypertensionaha.108.124008 · Cited by 379 · cited 4×
“Physiologically, BP displays a circadian rhythm, peaking during the day and decreasing, or dipping, during the night.12 Obese hypertensive patients with T2DM and/or renal or cardiovascular disease frequently demonstrate a blunted, or non-dipping, decrease in nocturnal BP.13 Non-dipping is associated with an increased…”
BackgroundInfluentialClinical Value of Ambulatory Blood Pressure: Evidence and Limits
Mancia, G., & Verdecchia, P. (2015) · Circulation Research · doi:10.1161/circresaha.116.303755 · Cited by 211
Mancia, G., Cannon, C. P., Tikkanen, I., Zeller, C., Ley, L., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.07703 · Cited by 128 · cited 1×
“In a further subgroup analysis of data from the EMPA-REG BP trial, empagliflozin was shown to reduce SBP and DBP irrespective of the number of antihypertensive medications that patients were receiving at baseline and irrespective of the type of antihypertensive used.(17) The BP-lowering effects of empagliflozin, in ad…”
Self-citation
Cited by
Zhao, Y., Xu, L., Tian, D., Xia, P., Zheng, H., Wang, L., & Chen, L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13101 · Cited by 333
Hypertension and Diabetes Mellitus: Coprediction and Time Trajectories
Tsimihodimos, V., Gonzalez-Villalpando, C., Meigs, J. B., & Ferrannini, E. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10546 · Cited by 295
Spallone, V. (2019) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2018.0259 · Cited by 295
Shao, Q., Meng, L., Lee, S., Tse, G., Gong, M., Zhang, Z., Zhao, J., Zhao, Y., Li, G., & Liu, T. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0964-4 · Cited by 293
The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
Wan, N., Rahman, A., Hitomi, H., & Nishiyama, A. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00421 · Cited by 115
Metadata
- Authors
- Chilton, R., Tikkanen, I., Hehnke, U., Woerle, H. J., & Johansen, O. E.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-07-07
- Volume
- 19
- Issue
- 11
- Pages
- 1620-1624
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2605285548
- Cited by
- 47
- References
- 6
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of empagliflozin on blood pressure in dipper and non‐dipper patients with type 2 diabetes mellitus and hypertension. https://app.cochat.ai/papers/10.1111/dom.12962
- The paper
- Chilton, R., Tikkanen, I., Hehnke, U., Woerle, H. J., & Johansen, O. E. (2017). Impact of empagliflozin on blood pressure in dipper and non‐dipper patients with type 2 diabetes mellitus and hypertension. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12962
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.